Richard A. Rudick

Sex differences in cytokine responses to myelin peptides in multiple sclerosis.

Factors that predict health-related quality of life in patients with relapsing-remitting multiple sclerosis.

Flow cytometric analysis of chemokine receptor expression on cerebrospinal fluid leukocytes.

Expression of CCR2, CCR5, and CXCR3 by CD4+ T cells is stable during a 2-year longitudinal study but varies widely between individuals.

Interferons in relapsing remitting multiple sclerosis.

Interferon gamma responses to myelin peptides in multiple sclerosis correlate with a new clinical measure of disease progression.

Interferon-beta 1a does not reduce expression of CCR5 and CXCR3 on circulating T cells.

Biologic impact of interferon antibodies, and complexities in assessing their clinical significance.

Atrophy is detectable within a 3-month period in untreated patients with active relapsing remitting multiple sclerosis.

Multiple sclerosis: disease markers accelerate progress.

Impact of disease-modifying therapies on brain and spinal cord atrophy in multiple sclerosis.

Defining interferon beta response status in multiple sclerosis patients.

Association of fatigue and brain atrophy in multiple sclerosis.

Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implications.

Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.

Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis.

Effects of sex hormones on costimulatory molecule expression in multiple sclerosis.

Primary progressive multiple sclerosis as a phenotype of a PLP1 gene mutation.

Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity.

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

Significance of T2 lesions in multiple sclerosis: A 13-year longitudinal study.

Should patients with relapsing multiple sclerosis be given a higher dose and frequency of interferon-beta1a?

Drug Insight: interferon treatment in multiple sclerosis.

Chemokine receptors as biomarkers in multiple sclerosis.

Imaging correlates of axonal swelling in chronic multiple sclerosis brains.

Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring.

Interferon-beta for multiple sclerosis: Long-term benefits?

Developing a mentorship program for clinical researchers.

Health-related quality of life in multiple sclerosis: effects of natalizumab.

Novel interferon-beta-induced gene expression in peripheral blood cells.

Interferon-beta treatment for multiple sclerosis.

Biomarkers for interferon response in MS: are we there yet?

Gray matter atrophy in multiple sclerosis: a longitudinal study.

LINGO-1 antagonists as therapy for multiple sclerosis: in vitro and in vivo evidence.

Health-related quality of life in multiple sclerosis: current evidence, measurement and effects of disease severity and treatment.

Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS.

Brain atrophy as an outcome measure for multiple sclerosis clinical trials: a "no-brainer"?

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.

Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis.

Disease modification in multiple sclerosis: issues with relevance to clinical trial designs in Alzheimer's disease.

Natalizumab for the treatment of relapsing multiple sclerosis.

Gray-matter injury in multiple sclerosis.

Do interferon beta-1b and glatiramer acetate grow brain?

Heterogeneous, longitudinally stable molecular signatures in response to interferon-beta.

Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.

A radical proposal: integrate clinical investigation into the U.S. health care system.

Patient-centered outcomes: translating clinical efficacy into benefits on health-related quality of life.

The multiple sclerosis functional composite: a clinically meaningful measure of disability.

Validation of a self-report comorbidity questionnaire for multiple sclerosis.

Measuring disability in relapsing-remitting MS.

Disability progression in a clinical trial of relapsing-remitting multiple sclerosis: eight-year follow-up.

Assessment of JC virus DNA in blood and urine from natalizumab-treated patients.

Multiple sclerosis: is multiple sclerosis caused by venous insufficiency?

Possible clinical outcome measures for clinical trials in patients with multiple sclerosis.

Web-based self-management for patients with multiple sclerosis: a practical, randomized trial.

Diagnostic criteria in multiple sclerosis: headed in the right direction but still a ways to go.

Beta-interferon for multiple sclerosis.

Challenges to clinical trials in multiple sclerosis: outcome measures in the era of disease-modifying drugs.

Excessive biologic response to IFNβ is associated with poor treatment response in patients with multiple sclerosis.

Oral treatment for multiple sclerosis.

The role of cell type-specific responses in IFN-β therapy of multiple sclerosis.

Multiple sclerosis, natalizumab, and PML: helping patients decide.

Risk stratification and patient counseling for natalizumab in multiple sclerosis.

MS clinical trials: what can subgroup analyses teach us?

The elusive biomarker for personalized medicine in multiple sclerosis: the search continues.

Multiple sclerosis or multiple possibilities: the continuing problem of misdiagnosis.

Early tolerability and safety of fingolimod in clinical practice.

Measurement and clinical effect of grey matter pathology in multiple sclerosis.

Time to integrate clinical and research informatics.

Predictors of long-term outcome in multiple sclerosis patients treated with interferon β.

Author response.

Author response to comment on "time to integrate clinical and research informatics".

Reliability of classifying multiple sclerosis disease activity using magnetic resonance imaging in a multiple sclerosis clinic.

MRI lesions: a surrogate for relapses in multiple sclerosis?

Preventing brain atrophy should be the gold standard of effective therapy in MS (after the first year of treatment): Yes.

Multiple Sclerosis Outcome Assessments Consortium: Genesis and initial project plan.

Assessing treatment response to interferon-β: is there a role for MRI?

Defining the clinical course of multiple sclerosis: The 2013 revisions.

Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study.